This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (14) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Major, J. Search for Related Content PubMed Articles by Major, J. Social Bookmarking                         What's this?

Challenges and Opportunities in High Throughput Screening: Implications for New Technologies

Lead Discovery Department, ZENECA Pharmaceuticals, Alderley Park, Cheshire, UK

In response to mounting competitive pressures, the current trend in the pharmaceutical industry is to shorten the time scale for all aspects of drug discovery. While advances in computation, structural chemistry, and molecular modeling are facilitating rational design activities, empirical screening continues to play a crucial role in lead identification. Because the ability to test large numbers of compounds quickly and efficiently can provide a competitive advantage, high throughput screening (HTS) has become a key tool in many companies. To achieve the necessary productivity, effective integration of compound supply, assay operation and data management is essential. HTS is a very high technology enterprise that must take full advantage of the latest advances in bioscience, biotechnology, engineering, and information science. There is a constant dilemma, however, in relation to when well-established, mature technologies should be replaced by new methods that promise to deliver spectacular advantages. The final decision must be based on weighing the promised benefit against the cost and risk. While huge challenges face the pharmaceutical industry, there are also opportunities for those companies that can identify and implement new technology effectively.

Journal of Biomolecular Screening, Vol. 3, No. 1, 13-17 (1998)
DOI: 10.1177/108705719800300102


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. J.W. Hole, P. W.A. Howe, P. D. Stanley, and S. T. Hadfield Pattern Recognition Analysis of Endogenous Cell Metabolites for High Throughput Mode of Action Identification: Removing the Postscreening Dilemma Associated with Whole-Organism High Throughput Screening J Biomol Screen, October 1, 2000; 5(5): 335 - 342. [Abstract] [PDF]

				M. Beggs, H. Blok, and J. Mertens Stacker Modules Used in a High-Capacity Robotics System for High Throughput Screening Compound Replication J Biomol Screen, December 1, 1999; 4(6): 373 - 379. [Abstract] [PDF]